Androgen Receptor NTD Inhibitor Solid Dispersion Formulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer and other AR-mediated disorders, such as castration-resistant prostate cancer, are limited due to the inability of conventional antiandrogens to effectively target the androgen receptor (AR) N-terminal domain (NTD), particularly constitutively active AR splice variants that lack the ligand-binding domain, leading to resistance and recurrence of the disease.
Innovation Solution
A pharmaceutical composition comprising a solid dispersion of Compound A, an androgen receptor N-terminal domain inhibitor, formulated with polymers like polyethylene glycol and polyvinyl pyrrolidone, which is administered in a form that enhances bioavailability and stability, allowing for effective modulation of AR activity and targeting of AR-positive cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiandrogens are used to treat prostate cancer, then they can target the androgen receptor ligand-binding domain, but they cannot effectively inhibit constitutively active AR splice variants that lack the ligand-binding domain, leading to treatment resistance
Solution Approach 1:
The invention extracts the ligand-binding domain requirement from the therapeutic approach by developing Compound A that directly targets the N-terminal domain. This allows inhibition of AR activity without needing to bind to the ligand-binding domain, thereby effectively treating constitutively active AR splice variants that lack this domain while conventional antiandrogens fail.
Solution Approach 2:
Compound A acts as an intermediary that binds to the N-terminal domain of the androgen receptor to inhibit its transcriptional activity. This intermediary approach allows the drug to modulate AR function through a different mechanism than conventional antiandrogens, enabling effective treatment of AR-mediated disorders regardless of ligand-binding domain presence.
2Quantity of substance
If Compound A is formulated as a solid dispersion, then solubility and bioavailability are improved, but the formulation complexity increases
Solution Approach 1:
The invention changes the physical state and dissolution parameters of Compound A by formulating it as a solid dispersion. This involves converting the compound into an amorphous or finely dispersed state within a carrier matrix, fundamentally altering its solubility and dissolution characteristics to achieve improved bioavailability.
Solution Approach 2:
The invention creates a composite pharmaceutical formulation by combining Compound A with carrier materials in a solid dispersion system. This composite approach integrates the active compound with excipients that facilitate dissolution and absorption, achieving enhanced bioavailability while maintaining manageable formulation complexity through established solid dispersion technologies.
Data Source
AI summary
The present disclosure generally relates to pharmaceutical compositions comprising N-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl) propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamideN-(4-((4-(2-(3-chloro-4-(2-chloroethoxy)-5-cyanophenyl) propan-2-yl)phenoxy)methyl)pyrimidin-2-yl)methanesulfonamide or a pharmaceutically acceptable salt, solvate, stereoisomer, or prodrug thereof. In particular, the present disclosure relates to solid dispersion pharmaceutical compositions useful for treatment of various cancers, for example breast cancer and prostate cancer.